Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
- 1 October 2020
- journal article
- letter
- Published by Elsevier in European Journal of Cancer
- Vol. 138, 169-171
Abstract
No abstract availableFunding Information
- Merck Sharp and Dohme United Kingdom
- Amgen
- Roche
- Bristol-Myers Squibb Canada
- Novartis Pharma
- Les Laboratories Pierre Fabre
This publication has 5 references indexed in Scilit:
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulationEuropean Journal of Cancer, 2020
- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetesClinical and Experimental Immunology, 2020
- Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for ManagementThe Oncologist, 2019
- Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysisTherapeutics and Clinical Risk Management, 2019
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018